Eculizumab

Results: 59



#Item
31ALN-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition Anna Borodovsky1; Kristina Yucius1; Andrew Sprague1; Nirmal K. Banda2; V. Michael Holers2; Akshay Vaishnaw1; Martin Maier1; Rajeev Kalla

ALN-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition Anna Borodovsky1; Kristina Yucius1; Andrew Sprague1; Nirmal K. Banda2; V. Michael Holers2; Akshay Vaishnaw1; Martin Maier1; Rajeev Kalla

Add to Reading List

Source URL: www.alnylam.com

Language: English - Date: 2014-12-06 10:10:48
32MEDICAL ASSISTANCE BULLETIN ISSUE DATE EFFECTIVE DATE

MEDICAL ASSISTANCE BULLETIN ISSUE DATE EFFECTIVE DATE

Add to Reading List

Source URL: www.dhs.state.pa.us

Language: English - Date: 2015-01-09 14:27:08
33

PDF Document

Add to Reading List

Source URL: www.worldcancercongress.org

Language: English - Date: 2014-12-19 06:09:36
34MEDICAL ASSISTANCE HANDBOOK  PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES 1.	 Requirements for Prior Authorization of Soliris (eculizumab) A.

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES 1. Requirements for Prior Authorization of Soliris (eculizumab) A.

Add to Reading List

Source URL: www.dhs.state.pa.us

Language: English - Date: 2014-12-29 17:37:38
35FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) FDA White Oak Campus, Building 31, the Great Room (Rm[removed]Whi

FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) FDA White Oak Campus, Building 31, the Great Room (Rm[removed]Whi

Add to Reading List

Source URL: www.fda.gov

Language: English
36Opening Remarks for Drug Safety and Risk Management Advisory Committee Meeting Cynthia LaCivita, PharmD, Acting Director Division of Risk Management Office of Medication Error Prevention and Risk Management

Opening Remarks for Drug Safety and Risk Management Advisory Committee Meeting Cynthia LaCivita, PharmD, Acting Director Division of Risk Management Office of Medication Error Prevention and Risk Management

Add to Reading List

Source URL: www.fda.gov

Language: English
37FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) FDA White Oak Campus, Building 31, the Great Room (Rm[removed]Whi

FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) FDA White Oak Campus, Building 31, the Great Room (Rm[removed]Whi

Add to Reading List

Source URL: www.fda.gov

Language: English
38AC Briefing  Drug Safety and Risk Management Advisory Committee (DSaRM[removed]

AC Briefing Drug Safety and Risk Management Advisory Committee (DSaRM[removed]

Add to Reading List

Source URL: www.fda.gov

Language: English
39Microsoft PowerPoint - 01_Cl_CoreIntro_111714_SMv1

Microsoft PowerPoint - 01_Cl_CoreIntro_111714_SMv1

Add to Reading List

Source URL: www.fda.gov

Language: English
40Updates to the Alberta Human Services Drug Benefit Supplement Effective November 1, 2014  Inquiries should be directed to:

Updates to the Alberta Human Services Drug Benefit Supplement Effective November 1, 2014 Inquiries should be directed to:

Add to Reading List

Source URL: www.ab.bluecross.ca

Language: English - Date: 2014-11-24 17:45:45